News

Excluding the comparison of $57 million in fourth-quarter 2008 sales of oxycodone hydrochloride extended-release tablets (Oxy ER), fourth-quarter 2009 operational growth (net sales growth excluding the effect of

YM BioSciences has presented preclinical results for Cyt997 at the Aacr-Nci-Eortc meeting Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts. The presentation was made by Cytopia. Cyt997

Abbott and BG Medicine have entered into a development and commercialisation agreement for galectin-3, a novel biomarker that may play a role in detecting the development and progression

According to a warning letter dated August 12, 2009 and posted on November 17, 2009 on FDA’s Web site, FDA conducted an inspection at Abbott Molecular facility in

SIRO Clinpharm, a global contract research organization (CRO) has reported alliance with Mediscis, an early drug development company based in Poitiers and La Rochelle, France. Chetan Tamhankar, chief

Novavax has completed the enrollment in the first stage of a two-stage clinical study of its novel 2009 H1N1 virus-like-particle (VLP) pandemic influenza unadjuvanted vaccine in the country

PanGenex has entered into a strategic partnership with BulovaTech Labs (LABS), a wholly-owned subsidiary of Bulova Technologies Group. The new partnership supports the joint development and commercialisation of

GlaxoSmithKline and GEA have formed a consortium to improve continuous processing and pharma manufacturing efficiency in the UK. The step was taken in response to the competition from

Mach 7 Technologies has made available a new revision, version 8.2 of its Keystone Suite Enterprise Management Platform. The new product release enhances the current product suite through